title: [The etiology and management of gout].
abstract: Gout is an inflammatory arthritis caused by monosodium urate (MSU) crystal deposits in and around the joint. The formation of urinary calculi can also occur in gout, but are less common than arthritis. Gout usually presents with recurrent episodes of joint inflammation, which over time lead to tophus formation and joint destruction. In the last decade, significant advances have been made regarding not only the epidemiology and genetics of gout and hyperuricemia but also the mechanisms of inflammation and treatment of gout. In addition, knowledge concerning the key role of interleukin 1 (IL-1) has provided new therapeutic perspectives. However, the current management of gout is often suboptimal, with many Patienten either not receiving adequate treatment or being unable to tolerate existing treatments. New therapeutic agents provide interesting new options for Patienten with difficult-to-treat gouty arthritis.The English full-text version of this is available at SpringerLink (under "Supplemental").
authors.affiliation: Department of Rheumatology, Centre Hospitalier Universitaire Vaudois, 1011, Lausanne, Suisse.
authors.forename: B
authors.initials: B
authors.lastname: Pazár Maldonado
authors.forename: A
authors.initials: A
authors.lastname: So
mesh_terms: D015210:Arthritis, Gouty / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology*; D003430:Cross-Sectional Studies; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006074:Gout Suppressants / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D053583:Interleukin-1beta / Q000037:antagonists & inhibitors / Q000502:physiology; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D006074:Gout Suppressants; D053583:Interleukin-1beta